Ipilimumab, a humanized monoclonal anti-CTLA-4 antibody, plus nivolumab, a PD-1 inhibitor, demonstrated an ORR of 0% in low- and intermediate-grade carcinoid tumors. This evidence concerns the gene PDCD1 and carcinoid tumor.